Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prognostic value of circulating proteins at diagnosis among patients with lung cancer: a comprehensive analysis by smoking status

X. Feng, HA. Robbins, A. Mukeriya, L. Foretova, I. Holcatova, V. Janout, J. Lissowska, M. Ognjanovic, B. Swiatkowska, D. Zaridze, P. Brennan, M. Johansson, M. Sheikh

. 2024 ; 13 (9) : 2326-2339. [pub] 20240927

Status not-indexed Language English Country China

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25002448

Grant support
001 World Health Organization - International

BACKGROUND: Improved prediction of prognosis among lung cancer patients could facilitate better clinical management. We aimed to study the prognostic significance of circulating proteins at the time of lung cancer diagnosis, among patients with and without smoking history. METHODS: We measured 91 proteins using the Olink Immune-Oncology panel in plasma samples that were collected at diagnosis from 244 never smoking and 742 ever smoking patients with stage I-IIIA non-small cell lung cancer (NSCLC). Patients were recruited from nine centres in Russian Federation, Poland, Serbia, Czechia, and Romania, between 2007-2016 and were prospectively followed through 2020. We used multivariable Survey-weighted Cox models to assess the relationship between overall survival and levels of proteins by adjusting for smoking, age at diagnosis, sex, education, alcohol intake, histology, and stage. RESULTS: The 5-year survival rate was higher among never than ever smoking patients (63.1% vs. 46.6%, P<0.001). In age- and sex-adjusted survival analysis, 23 proteins were nominally associated with overall survival, but after adjustment for potential confounders and correcting for multiple testing, none of the proteins showed a significant association with overall survival. In stratified analysis by smoking status, IL8 [hazard ratio (HR) per standard deviation (SD): 1.40, 95% confidence interval (CI): 1.18-1.65, P=1×10-4] and hepatocyte growth factor (HGF) (HR: 1.45, 95% CI: 1.18-1.79, P=5×10-4) were associated with survival among never smokers, but no protein was found associated with survival among ever smokers. Integrating proteins into the models with clinical risk factors did not improve the predictive performance of NSCLC prognosis [C-index of 0.63 (clinical) vs. 0.64 (clinical + proteins) for ever smokers, P=0.20; C-index of 0.68 (clinical) vs. 0.72 (clinical + proteins) for never smokers, P=0.28]. CONCLUSIONS: We found limited evidence of a potential for circulating immune- and cancer-related protein markers in lung cancer prognosis. Whereas some specific proteins appear to be uniquely associated with lung cancer survival in never smokers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002448
003      
CZ-PrNML
005      
20250123101931.0
007      
ta
008      
250117s2024 cc f 000 0|eng||
009      
AR
024    7_
$a 10.21037/tlcr-24-242 $2 doi
035    __
$a (PubMed)39430322
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a cc
100    1_
$a Feng, Xiaoshuang $u Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
245    10
$a Prognostic value of circulating proteins at diagnosis among patients with lung cancer: a comprehensive analysis by smoking status / $c X. Feng, HA. Robbins, A. Mukeriya, L. Foretova, I. Holcatova, V. Janout, J. Lissowska, M. Ognjanovic, B. Swiatkowska, D. Zaridze, P. Brennan, M. Johansson, M. Sheikh
520    9_
$a BACKGROUND: Improved prediction of prognosis among lung cancer patients could facilitate better clinical management. We aimed to study the prognostic significance of circulating proteins at the time of lung cancer diagnosis, among patients with and without smoking history. METHODS: We measured 91 proteins using the Olink Immune-Oncology panel in plasma samples that were collected at diagnosis from 244 never smoking and 742 ever smoking patients with stage I-IIIA non-small cell lung cancer (NSCLC). Patients were recruited from nine centres in Russian Federation, Poland, Serbia, Czechia, and Romania, between 2007-2016 and were prospectively followed through 2020. We used multivariable Survey-weighted Cox models to assess the relationship between overall survival and levels of proteins by adjusting for smoking, age at diagnosis, sex, education, alcohol intake, histology, and stage. RESULTS: The 5-year survival rate was higher among never than ever smoking patients (63.1% vs. 46.6%, P<0.001). In age- and sex-adjusted survival analysis, 23 proteins were nominally associated with overall survival, but after adjustment for potential confounders and correcting for multiple testing, none of the proteins showed a significant association with overall survival. In stratified analysis by smoking status, IL8 [hazard ratio (HR) per standard deviation (SD): 1.40, 95% confidence interval (CI): 1.18-1.65, P=1×10-4] and hepatocyte growth factor (HGF) (HR: 1.45, 95% CI: 1.18-1.79, P=5×10-4) were associated with survival among never smokers, but no protein was found associated with survival among ever smokers. Integrating proteins into the models with clinical risk factors did not improve the predictive performance of NSCLC prognosis [C-index of 0.63 (clinical) vs. 0.64 (clinical + proteins) for ever smokers, P=0.20; C-index of 0.68 (clinical) vs. 0.72 (clinical + proteins) for never smokers, P=0.28]. CONCLUSIONS: We found limited evidence of a potential for circulating immune- and cancer-related protein markers in lung cancer prognosis. Whereas some specific proteins appear to be uniquely associated with lung cancer survival in never smokers.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Robbins, Hilary A $u Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
700    1_
$a Mukeriya, Anush $u Department of Clinical Epidemiology, N.N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia
700    1_
$a Foretova, Lenka $u Department of Cancer Epidemiology & Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Holcatova, Ivana $u Department of Public Health and Preventive Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Oncology, University Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Janout, Vladimir $u Faculty of Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Lissowska, Jolanta $u Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Ognjanovic, Miodrag $u International Organization for Cancer Prevention and Research, Belgrade, Serbia
700    1_
$a Swiatkowska, Beata $u Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland
700    1_
$a Zaridze, David $u Department of Clinical Epidemiology, N.N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia
700    1_
$a Brennan, Paul $u Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
700    1_
$a Johansson, Mattias $u Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
700    1_
$a Sheikh, Mahdi $u Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
773    0_
$w MED00186389 $t Translational lung cancer research $x 2218-6751 $g Roč. 13, č. 9 (2024), s. 2326-2339
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39430322 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101925 $b ABA008
999    __
$a ok $b bmc $g 2254580 $s 1238451
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 13 $c 9 $d 2326-2339 $e 20240927 $i 2218-6751 $m Translational lung cancer research $n Transl Lung Cancer Res $x MED00186389
GRA    __
$a 001 $p World Health Organization $2 International
LZP    __
$a Pubmed-20250117
Back

Find record

Citation metrics

Archiving options